Indian Pharma Market Registers 8.5% Growth In Dec 2020

Mumbai : The Indian Pharmaceutical Market (IPM) has registered a growth of 8.5 per cent for the month of December 2020, as against growth of one per cent in November 2020.

According to AIOCD AWACS report, the IPM has recorded sales of Rs. 1,45,354 crore for moving annual total (MAT) basis during December 2020.

Amongst the top 10 corporates, Cipla exhibited the highest growth of 8.9 per cent, followed by Torrent Pharma at 7.0 per cent.  Amongst the 11 to 25 ranked corporates, Glenmark Pharma exhibited highest growth of 16.3 per cent followed by Himalaya at 14.1 per cent.

Amongst the 26 to 50 ranked corporates, Apex Lab registered the highest growth of 20.1 per cent followed by Boehringer Ingelheim at 14.4 per cent. Amongst the 51 to 75 ranked corporates, Danone registered the highest growth of 33.5 per cent. Amongst the 76 to 100 ranked corporates, Reckitt Benckiser exhibited the highest growth at 23.6 per cent, followed by Llyod Hc at 14.4 per cent.

Some therapies continue the trend of revival in December 2020.Cardiac registered a monthly growth of 14.9% as compared to 8.7% in November 2020, while anti-diabetic registered growth of 9.9% in December 2020 as compared to 1.9% in November 2020.While respiratory medicines growth slumps to -8.7% in December 2020 as compared to -6.9 % in November 2020.

Post unlockdown since June 2020 the struggle for anti-infectives at 0.2% in November 2020 continues 5.2% in December 2020 and its associated therapy like gastro exhibits growth of 16.2% in December 2020 as against 3.1% in November 2020.

Vitamins have bounced back has growth of 14.0% in December 2020 as compared to 6.6 % in November 2020 and pain and analgesics are at  6.0% in December 2020 as against -5.2% in November 2020.

  • Related Posts

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Andelyn bio sciences Inc, a leading patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Queen’s University to develop and manufacture AAV9-GM2, a gene therapy…

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    Cellution Biologics Inc, a biologics company focused on developing, manufacturing and commercializing advanced human tissue-based products, announced the completion of its acquisition of the SimpliDerm hydrated human acellular dermal matrix…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Andelyn Biosciences partners with Queen’s University to develop and manufacture gene therapy AAV9-GM2 to treat GM2 gangliosidoses

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    Cellution Biologics completes acquisition of SimpliDerm business for US$ 8 million from Elutia

    ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

    ACB Gujarat arrested two FDA Officials red-handed in Bharuch accepting a bribe of ₹40,000

    US appeals court sides with Sun Pharma in Lipitor antitrust case

    US appeals court sides with Sun Pharma in Lipitor antitrust case

    Counterfeit Cosmetics Are No Longer a Fringe Problem: 4 in 10 Consumers Report Fake Products, Regulatory Silence Raises Serious Questions

    Counterfeit Cosmetics Are No Longer a Fringe Problem: 4 in 10 Consumers Report Fake Products, Regulatory Silence Raises Serious Questions

    Three arrested for illegal sale of mephentermine sulphate injections in Hyderabad

    Three arrested for illegal sale of mephentermine sulphate injections in Hyderabad